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SHORT COMMUNICATION
Anticancer efficacy of 2-chloroethylnitrosocarbamoyl derivatives of L-
alanine, glycine, their di- and tripeptide homologues and the respective
amides in methylnitrosourea-induced rat mammary carcinoma
T. Klenner, M.R. Berger, G. Eisenbrand1 & D. Schmahl
Institute of Toxicology and Chemotherapy, German Cancer Research Center, FRG; and 1Department of Food Chemistry and
Environmental Toxicology, Universty of Kaiserslautern, Kaiserslautern, FRG.
2-Chloroethyl-N-nitrosoureas are known to have high anti-
cancer activity while being limited in their clinical use by
delayed and pronounced toxicity to all rapidly proliferating
tissues, especially the bone-marrow. Recently new com-
pounds derived from L-alanine and glycine have been synthe-
sised (Ehresmann et al., 1984) and examined against
transplantable tumour models (Zeller et al., 1984; Zeller,
1985, 1986). The results of these experiments suggested
further investigation of these compounds against solid
tumours. Therefore the solid autochthonous mammary carci-
noma, induced with methylnitrosourea which mimics the
human counterpart to a high extent (Berger & Zeller, 1984;
Wilkinson et al., 1986) was used to allow an estimation of
anticancer efficacy and toxicity. N-methyl-N-nitrosourea
(MNU) was kindly provided by Professor Dr M. Wiessler
(Institute of Toxicology and Chemotherapy, German Cancer
Research Center, Heidelberg). All other compounds were
synthesised as published recently (Ehresmann et al., 1984;
Eisenbrand et al., 1983; Tang & Eisenbrand, 1981; Zeller et
al., 1979). The substances were homogenous by thin-layer
chromatography and high-pressure liquid chromatography
and were characterised spectroscopically (IR, UV, NMR).
Chemical formulas, names and the abbreviations used are
listed in Table I.
Virgin female Sprague-Dawley rats (Zentralinstitut fur
Versuchstierzucht, Hannover, FRG) were kept under
standard conventional conditions. Altromin pellets and tap-
water were given ad libitum.
Mammary carcinomas were induced by i.v. administration
of MNU according to published methods (Berger et al.,
1983). Individual tumour volumes were estimated by palpa-
tion up to a volume of 0.8cm3; larger tumours were
estimated by vernier calipers measuring two vertical axes
according to the formula axb2/2, a<b.
The total tumour volume per animal was calculated as the
sum of all individual tumours. Animals with a total tumour
volume of at least 0.8cm3 were randomly allocated to
experimental groups. The treatment (see Tables II and III)
started immediately thereafter.
All substances were dissolved in DMSO immediately
before use and i.p. administered on days 1, 8, 22 and 29
following randomisation. A logarithmically scaled range of
doses was obtained using the factor 1.5. Toxicity was
checked using the parameters body weight difference and
mortality. The body weight difference was calculated as the
median body weight at the end of treatment (week 6) minus
the median initial body weight (week 1) in % of initial body
weight. Mortality represents the number and percentage of
animals which had died until the end of therapy (week 6).
Therapeutic efficacy was measured on the basis of the
median total tumour volume of treated groups versus control
group x 100 (T/C %). The number of tumours refers to the
median number of tumours per rat and group at the week
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indicated. Additionally, the increase in life span was calcu-
lated as the mean survival time of the respective treated
group minus that of the control group in % of the control
group (ILS%), to obtain data on the long-term toxicity of
the treatment.
Significant differences in tumour volume were determined
according to a multivariate rank sum test as described by
Koziol & Donna (1981). The test was applied to all groups,
except those with a mortality greater than 20% during the
treatment period. This limit was chosen because untreated
controls showed a comparable mortality rate within that
time (Tables IV and V) and because the limit should slightly
exceed that of controls to be able to discern drug-induced
toxicity. Differences in survival times were evaluated by the
Kaplan-Meier method, using the log rank test (Kalbfleisch
& Prentice, 1980). Differences in tumour numbers per rat
and group were considered significant, if the 95% confidence
limits of the median tumour number did not overlap
(P<0.05). The Kruskal-Wallis test was also applied. The
graph of the two control-groups (group A I+B I; Figure 1)
was performed by adding the median of the differences of all
tumour volumes each week. Thus, a 'false remission' caused
by early deaths of animals from these groups did not
influence the curve and only real remissions of tumour
volume can be observed.
The results of investigating nine CNC-L-alanine-
derivatives, their corresponding di- and tripeptides and their
respective amides and methylamides in comparison to
untreated controls are summarised in Table IV.
The control group (A I, Table IV) showed a steady rise in
median tumour volume up to week 5 and decreased slightly
thereafter due to a minor regression in tumour volume
caused by exulceration of some tumours (Figure 1). The
tumour volume doubling time of this group between weeks 1
and 6 was 7.9 days and the mean survival time 76 + 15 days.
Of the L-alanine-derivatives the free amino acid-derivatives
showed the highest activity (groups A II and A V) demon-
strated by significant inhibition of tumour volume and of
tumour number compared to the controls. CNC-ala-ala was
the most effective L-alanine-derivative, displaying significant
inhibition in tumour volume as well as tumour number and
a low toxicity. CNC-ala-NH2 (group A III) also had a
significant tumour-inhibiting effect but at the same time
caused a high toxicity (Table IV). CNC-ala-NH-CH3 (group
A IV) also had a high toxicity coupled with good antitumour
efficacy. The dipeptide derivative CNC-ala-ala-NH2 (group
A VI) showed a poor effect on tumour volume (Figure 2)
but a high mortality rate. CNC-ala-ala-NH-CH3 (group
A VII) displayed a dose-dependent non-significant cytotoxic
effect. No apparent toxicity was observed. The tripeptide
derivatives (groups A VIII, IX, X; Tables I and IV) were
overall not effective in inhibiting the tumour growth and
were only moderately toxic.
The results of investigating nine corresponding glycine
derivatives are shown in Table V. The control group (B I,
Table V) showed an increase in median tumour volume up
to week 4 and reached its maximum at week 8, remaining
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Table I Overview of selected
,roup no. Chemical formula
9 9
A If Cl-CH,-CH,-N-C-N-CH-C-0H
=oH CH,
9 9
A III Cl-CH2-CH,-N-C-N-CH-C- NH,
N H CH,
9 9
A IV Cl-CH,-CHj-N-C-N-CH-C-NH-CH,
soHCH.
9 9 9
A V Cl-CH2-CH2-N-C-N-CH-C-N-CH-C-OH
NHC HCH. ACH,
9 9 9? A Vil C-CH,-CH-N-C-N-CH-C-N-CH-C-N-CH-C-OHI
N.0 H C!H, H CH, H CH,
9 9
B 11 Cl-CH,-CH2-N-CN-CH,-C-OH
9 9
B 111 Cl-CH.-CH,-N-C-N-CHC-NH,
0 9 9
B IV Cl-CH,-CH,-N-C-N-CHFC-NH-CH,
No H
a V Cl-CH,-CH2-N-C-N-CH,-C-N-CM2-C-Ot
N+o HH 0~~~~
B Vill CI-CH,-CH,-N-C-N-CHfC-N-CH,-7-N-CH,--OH
NoH H H
CNC =N-(2-chloroethyl)-N-nitroso-N'-carbamoyl.
compounds' formula, name and abbreviation
Chemical name
CNC-L-alanine
CNC-L-alanine-amide
CNC-L-alanine-methylamide
CNC-L-alanyl-L-alanine
CNC-L-alanyl-L-alanyl-L-alanine
CNC-glycine
CNC-glycine-amide
CNC-glycine-methylamide
CNC-glycyl-glycine
CNC-glycyl-glycyl-glycine
Abbreviation
CNC-ala
CNC-ala-NH2
CNC-ala-NH-CH3
CNC-ala-ala
CNC-ala-ala-ala
CNC-gly
CNC-gly-NH2
CNC-gly-NH-CH2
CNC-gly-gly
CNC-gly-gly-gly
Table II Design of experiment: therapy of MNU-induced mammary carcinoma in female SD-rats with CNC-
linked di- and oligopeptides (aminoacid L-alanine)
Median
total dose Number
Group Dose
Compound no. (,imolkg-
Control A I
CNC-alaa A Ila 45
b 67
c 101
CNC-ala-NH2 A Illa 20
b 30
c 45
CNC-ala-NH-CH3 A IVa 20
b 30
c 45
CNC-ala-alaa A Va 45
b 67
c 101
CNC-ala-ala-NH2 A VIab 20
bb 30
c 45
CNC-ala-ala-NH-CH3 A VIla 20
b 30
c 45
CNC-ala-ala-ala A VIlla 45
b 67
c 101
CNC-ala-ala-ala-NH2 A IXa 30
b 45
c 67
CNC-ala-ala-ala-NH-CH3 A Xa 20
b 30
c 45
'This compound was tested in a different experiment.
bThis dosage was tested in a different experiment.
1)
Dose
(mgkg-1)
10.0
15.0
22.5
4.4
6.7
10.0
4.7
7.1
10.7
13.3
19.9
29.8
5.9
8.8
13.2
6.2
9.2
13.8
16.5
24.7
37.0
10.9
16.4
24.6
7.6
11.4
17.0
(range)
(mgkg1
40.0 (40.0)
60.0 (30.0-60.0)
90.0 (45.0-90.0)
17.6 (17.6)
26.8 (26.8)
35.0 (30.0-40.0)
18.8 (9.2-18.8)
28.4 (28.4)
42.8 (42.8)
53.2 (53.2)
78.8 (39.4-78.8)
119.2 (59.6-119)
23.6 (23.6)
30.8 (17.6-35.2)
26.4 (13.2-52.8)
24.8 (24.8)
36.8 (36.8)
55.2 (55.2)
66.0 (66.0)
98.8 (98.8)
148.0 (37.0-148)
43.6 (43.6)
65.6 (65.6)
98.2 (49.2-98.2)
30.4 (22.8-30.4)
45.6 (45.6)
68.0 (51.0-68.0)
G
Of
animals
20
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
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Table III Design of experiment: therapy of MNU-induced mammary carcinoma in female SD-rats with CNC-
linked di- and oligopeptides (aminoacid glycine)
Compound
Control
CNC-gly
CNC-gly-NH2
CNC-gly-NH-CH3
CNC-gly-gly
CNC-gly-gly-NH2
CNC-gly-gly-NH-CH3
CNC-gly-gly-gly
CNC-gly-gly-gly-NH2
CNC-gly-gly-gly-NH-CH3
Group
no.
B I
B Ila
b
c
B Illa
b
c
B IVa
b
c
B Va
b
c
B VIa
b
c
B VIla
b
c
B VIlla
b
c
B IXa
b
c
B Xa
b
c
Dose Dose
(pmolkg'- ) (mgkg-)
45
67
101
20
30
45
30
45
67
30
45
67
20
30
45
30
45
67
30
45
67
30
45
67
20
30
45
9.4
14.1
21.2
4.2
6.3
9.4
6.7
10.0
15.0
8.0
12.0
18.0
5.3
8.0
12.0
8.3
12.6
18.9
9.6
14.5
21.8
9.7
14.5
21.8
6.7
10.1
15.1
Median
total dose
(range)
(mgkg-)
37.6 (37.6)
56.4 (56.4)
42.4 (21.2-84.8)
16.8 (16.8)
25.2 (25.2)
37.6 (37.6)
26.8 (26.8)
40.0 (40.0)
30.0 (30.0-60.0)
32.0 (32.0)
48.0 (48.0)
72.0 (36.0-72.0)
21.2 (21.2)
32.0 (32.0)
48.0 (48.0)
33.2 (33.2)
50.4 (50.4)
75.6 (75.6)
38.4 (38.4)
58.0 (58.0)
87.2 (87.2)
38.8 (38.8)
58.0 (58.0)
87.2 (21.8-87.2)
26.0 (26.0)
40.4 (40.4)
60.4 (60.4)
constant thereafter (Figure 1). This control group had a
tumour volume doubling time of about 7.7 days, over the
first 6 weeks, and a mean survival time of 59+7 days.
The glycine-derivatives were more active, compared to the
L-alanine-derivatives and especially the methylamide-derived
compounds showed superiority. This could be demonstrated
by significant inhibition of tumour volume and of tumour
number compared to controls. Out of the glycine series the
compound CNC-gly (Group B II) was considered most effec-
tive, due to significant increase in life span and reduction of
tumour volume. CNC-gly-NH2 (group B III) showed a dose-
dependent inhibition of the median tumour volume
(Table V) and increasing toxicity with increasing dosage.
CNC-gly-NH-CH3 (group B IV) inhibited tumour growth
and tumour number significantly at the lowest dose, but the
antitumour effects following the higher doses were meaning-
less due to a marked toxicity. This compound was con-
sidered very potent as shown by T/C% values of the low
dose (Figure 3). CNC-gly-gly (group B V) displayed signifi-
cant tumour growth inhibition at its high dose only. Toxicity
was low in all doses (Table V).
CNC-gly-gly-NH2 (group B VI) effected a dose-dependent
inhibition of the median tumour volume and the median
tumour number. Toxicity was similar at all three doses.
CNC-gly-gly-NH-CH3 (group B VII) displayed a dose-
dependent, significant tumour-inhibiting effect. Toxicity was
moderate and not dose-related. CNC-gly-gly-gly (group
B VIII) showed no significant tumour inhibition and no
toxicity. CNC-gly-gly-gly-NH2 (group B IX) inhibited the
median tumour volume in a dose-related manner with the
two high doses displaying significant anticancer activity
Table V). CNC-gly-gly-gly-NH-CH3 (group B IX) showed
no significant inhibition of median tumour volume or
median tumour number. The body-weight differences were
positive and the mean life spans were increased.
Significantly lower tumour numbers - as assessed by the
Kruskal-Wallis test for optimal doses - were found at week
6 only in groups treated with CNC-gly 14.1 mgkh 1 (B Ilb),
CNC-gly-NH-CH3 6.7mgkg-1 (B IVa), CNC-gly-gly
18.0 mgkg- 1 (B Vc), CNC-gly-gly-NH2 12.Omgkg- 1
(B VIc), and CNC-gly-gly-NH-CH3 18.9mgkg-1 (B Vllc).
Additionally, significant differences were already found at
week 3 for groups treated with CNC-gly (B Ila) and CNC-
gly-NH-CH3 (B IVa) (data not shown).
The tumour growth in untreated controls of the two
experimental series (Figure 1) showed a typical variability,
which implied that comparisons between experiments A and
C.) E
E
Co
.0
0)
Time (weeks)
Figure 1 Median tumour volumes of controls A and B includ-
ing 95% confidence limits (differences of median tumour volumes
were added up each week to eliminate effects of dying animals
within the observed period). 0, control A; *, control B.
Number
of
animals
20
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
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Table IV Therapeutic eflicacy of alanine-linked chloroethylnitrosocarbamoylderivatives
Compound
Control
CNC-ala
CNC-ala-NH2
CNC-ala-NH-CH3
CNC-ala-ala
CNC-ala-ala-NH2
CNC-ala-ala-NH-CH3
CNC-ala-ala-ala
CNC-ala-ala-ala-NH2
CNC-ala-ala-ala-NH-CH3
Group
no.
A I
A Ila
b
c
A Illa
b
c
A IVa
b
c
A Va
b
c
A VIa
b
c
A VIla
b
c
A VIlla
b
c
A IXa
b
c
A Xa
b
c
Tmour
volume
week 6C
19.0 (15.2-38.1)
20.6 (7.2-28.0)
6.9 (1.5-15.1)
11.0 (0.7-18.7)
8.9 (5.2-22.3)
6.6 (2.5-14.0)
0.3 (0.0- 2.7)
15.0 (9.6-23.1)
7.3 (3.3-11.9)
3.4 (0.1- 8.0)
19.2 (18.3-31.4)
16.6 (7.2-21.4)
10.7 (0.0-28.2)
18.0 (13.4-27.8)
12.6 (3.9-23.9)
25.7 (20.4-29.9)
18.3 (9.3-23.3)
12.6 (3.9-24.6)
16.6 (11.0-23.2)
9.4 (6.9-25.6)
4.5 (0.9-44.6)
27.0 (9.4-43.6)
19.7 (1.5-60.2)
13.1 (10.1-40.0)
21.9 (15.1-30.7)
10.6 (6.7-30.4)
15.9 (9.5-31.4)
Number
of tumours
P week 6c
10 (8-10)
n.s.d 8 (7-10)
n.d.e 6 (2-12)
n.d.e 7 (2-8)
0.0384f 7 (5-11)
n.s.d 7.5 (2-12)
n.d.e 2 (0-4)
n.s.d 9 (7-13)
0.0016f 6.5 (3-11)
0.0016f 3.5 (1-5)
n.s.d 8.5 (6-11)
n.s.d 9 (7-11)
0.0020f 6 (3-7)
n.s.d 11 (8-13)
n.d.e 9.5 (4-12)
n.d.e
n.s.d 10 (8-11)
n.s.d 9 (8-11)
n.s.d 8 (8-10)
n.s.d 8.5 (6-11)
n.s.d 8 (6-10)
0.0224f 6 (4-10)
n.s.d 10.5 (2-12)
n.s.d 8.5 (2-13)
n.d.e 11 (2-13)
n.s.d 10.5 (4-12)
n.s.d 11 (6-14)
n.s.d 10 (7-11)
BWDa
-3.1
+12.5
-3.1
-10.2
-6.2
-3.2
-18.7
0
-2.1
-19.1
+12.5
-2.1
-2.2
+18.5
+14.6
+4.0
+4.0
+7.3
+ 3.2
-3.3
-1.1
+1.1
-5.1
0
-2.0
+3.1
+4.3
Mortality
n (%)
week 6
3 (15)
0 (0)
3 (30)
6 (60)
0 (0)
2 (20)
5 (50)
1 (10)
0 (0)
0 (0)
1 (10)
1 (10)
2 (20)
1 (10)
4 (40)
9 (90)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (20)
2 (20)
2 (20)
3 (30)
2 (20)
0 (0)
1 (10)
ILSb
(0)
-14
-40
-3
-26
-49
-14
-7
-22
+15
-3
-5
-23
-70
-19
-16
-16
-1
+0
-17
-7
-10
-23
-25
+5
-8
aBody weight difference: median body weight at treatment end (week 6) minus median initial body weight (week 1) in % of initial
weight.
bIncrease in life span: mean survival time of treated animals minus mean survival time of control rats in % of control.
cMedian of group (95% confidence limits).
dn.s. =not significant according to Koziol & Donna (1981).
en.d.=not determined.
fSignificant according to Koziol & Donna (1981).
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Figure 2 T/C% values of CNC-linked L-alanines at weeks 3 and 6 ( 0 lowest dose, 10 medium dose, U highest dose). 0-1=CNC-
ala; 2-3 =CNC-ala-NH2; 4-5 =CNC-ala-NH-CH3; 6-7 =CNC-ala-ala; 8-9 =CNC-ala-ala-NH2; 10-11=CNC-ala-ala-NH-CH3;
12-13 =CNC-ala-ala-ala; 14-15 =CNC-ala-ala-ala-NH2; 16-17 =CNC-ala-ala-ala-NH-CH3.2-CHLOROETHYLNITROSOCARBAMOYL DERIVATIVES 339
Table V Therapeutic efficacy of glycine-linked chloroethylnitrosocarbamoylderivatives
Tumour Number Mortality
Group volume of tumours n (%) ILSb
Compound no. week 6c p week 6C BWDa week 6 (%)
Control B I 31.8 (23.6-38.6) 13 (12-14) +3.3 2 (10) -
CNC-gly B Ila 13.1 (10.1-21.7) 0.0133f 12 (11-13) +4.9 0 (0) +239
b 10.1 (0.6-18.4) O.OOl9f 7.5 (4-12) -7.4 0 (0) +2
c 7.0 (4.4-10.8) n.d.e 5 (3- 7) -8.5 6 (60) -44
CNC-gly-NH2 B Illa 13.0 (7.3-18.8) 0.0057f 10 (9-12) -1.2 0 (0) +4
b 7.0 (2.3-16.1) O.Ol90f 9 (8-12) -10.4 1 (10) -4
c 3.9 (0.2- 5.1) n.d.e 7 (2- 9) -11.0 6(60) -35
CNC-gly-NH-CH3 B IVa 2.2 (0.6- 4.5) 0.0019f 6.5 (4-10) -13.6 0 (0) -15
b 3.7 (0.1- 9.0) n.d.e 4 (1- 9) -17.8 5 (50) -38
c - - n.d.e - _- 9 (90) -60
CNC-gly-gly B Va 27.0 (20.8-34.9) n.s.d 14 (10-15) +9.8 0 (0) + 1
b 19.9 (14.3-34.9) n.s.d 12 (9-15) +9.9 0 (0) +46
c 9.4 (2.6-26.3) O.OOl9f 10 (4-11) -3.4 1 (10) +8
CNC-gly-gly-NH2 B VIa 14.7 (8.1-19.0) n.s.d 12 (9-13) +6.0 1 (10) -3
b 13.6 (10.6-23.1) n.s.d 11 (7-12) -2.0 1 (10) -20
c 8.0 (2.2-14.3) 0.0096f 10 (5-11) -2.1 1 (10) -16
CNC-gly-gly-NH-CH3 B VIla 10.3 (3.2-25.6) 0.0228f 11 (8-13) +0.1 2 (20) -9
b 8.9 (4.3-22.3) n.s.d 9 (5-12) -5.3 1 (10) -2
c 6.7 (0.9-27.9) 0.0285f 5.5 (3-12) -7.1 2 (20) -26
CNC-gly-gly-gly B Vllla 23.7 (13.4-38.5) n.s.d 11 (9-13) +15.4 0 (0) +38
b 26.5 (14.5-38.1) n.s.d 11 (9-13) +5.0 0 (0) +11
c 15.8 (10.0-31.6) n.s.fd 11 (9-11) +11.3 1 (10) +15
CNC-gly-gly-gly-NH2 B IXa 21.9 (11.5-33.2) n.s.d 10.5 (5-12) +6.8 0 (0) +7
b 10.8 (2.7-16.2) O.OOl9f 9 (4-13) +2.1 2 (20) -3
c 6.2 (0.2-16.2) n.d.e 7 (3-11) -3.4 3 (30) -21
CNC-gly-gly-gly-NH-CH3 B Xa 21.9 (13.2-34.3) n.s.d 11 (10-15) +11.6 1 (10) +7
b 17.9 (13.7-29.7) n.s.d 12.5 (10-14) +9.9 0 (0) +14
c 13.9 (11.4-35.2) n.s.d 10 (10-12) +8.0 1 (10) +8
aBody weight difference: median body weight at treatment end (week 6) minus median initial body weight (week 1) in % of initial
body weight.
bIncrease in life span: mean survival time of treated animals minus mean survival time of control rats in % of control.
cMedian of group (95% confidence limits).
dn.s.=not significant according to Koziol & Donna (1981).
en.d.=not determined.
fSignificant according to Koziol & Donna (1981).
gSignificant according to Kaplan-Meier estimate (Kalbfleisch & Prentice, 1980).
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Figure 3 T/C% values of CNC-linked glycines at weeks 3 and 6 (L lowest dose, E medium dose, M highest dose). 0-1=CNC-
gly; 2-3 =CNC-gly-NH2; 4-5 =CNC-gly-NH-CH3; 6-7 =CNC-gly-gly; 8-9=CNC-gly-gly-NH2; 10-11 =CNC-gly-gly-NH-CH3;
12-13 =CNC-gly-gly-gly; 14-15 =CNC-gly-gly-gly-NH2; 16-17 =CNC-gly-gly-gly-NH-CH3.340 T. KLENNER et al.
B were based on tumour inhibition relative to the respective
control (T/C%; Figures 2 and 3).
The results show an overall better therapeutic efficacy of
the glycine compared to the L-alanine-derivatives. For both
series a clear dose dependency and a loss of anticancer
activity is evident with increasing chain length. For the
alanine-derivatives the free amino acids were superior to the
methylamides and these again over the amides (Table IV).
The highest tumoricidal effect of the glycine-derivatives,
however, was observed for the methylamides of CNC-gly
and CNC-gly-gly.
The amino acid an dipeptide-derivatives of this series had
a comparable effect, but the dipeptides were less toxic at
equimolar doses and slightly less active. It must be noted
that the antineoplastic efficacy of the amide-derivatives of
glycine did not decrease with rising chain length whereas the
methylamide-derivatives of the tripeptides lost their activity
in both series investigated.
The glycine-derivatives were also superior to the alanine-
derivatives with respect to increase in life span, as evidenced
by CNC-gly and CNC-gly-gly-gly, which both effected a
significant increase in this parameter (groups B Ila and
B Vllla, Table IV). The majority of compounds, however,
caused a reduced life expectancy.
These data are very comparable with previous experiments
using the cinically established nitrosoureas BCNU and chlor-
ozotocin against 7,12-dimethylbenz(a)anthracene(DMBA)-
induced rat mammary carcinoma (Fiebig et al., 1980). These
agents also reduced the life expectancy in comparison to
controls and effected T/C values of 35 and 46%,
respectively.
The high antitumour effect of the methylamides seen in
experiments on transplantable adenocarcinomata of mouse
colon (Bibby & Double, 1986) could not be observed in
these investigations using the MNU-induced autochthonous
rat mammary carcinoma.
Altogether, no prediction of anticancer activity could be
made from the CNC-glycine series to the CNC-L-alanine
derivatives or vice versa. These findings show that minor
changes in the amino acid structure might cause unpredic-
table alterations in activity (cf. the high toxicity of glycine-
based methylamides in comparison to the low toxicity of the
respective alanine congeners).
From these findings it can be said that profound infor-
mation on the anticancer activity of other aminoacid deriva-
tives needs additional investigations. In conclusion, the high
antitumour activity of amide, methylamide and oligopeptide-
derivatives of glycine and L-alanine linked to the CNC-
moiety against experimental leukaemias (Zeller, 1985, 1986;
Zeller et al., 1984) and transplantable adenocarcinomata of
mouse colon (Bibby & Double, 1986) could not be con-
firmed in this solid tumour model.
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